SGHT guidance is weak and hopefully a reflection of them losing share.
"Sight Sciences projects revenue for full year 2024 to range from approximately $81.0 million to $85.0 million, representing a range of 0% to 5% growth compared to 2023. The Company expects double-digit revenue growth in the second half of 2024 versus the comparable periods in the prior year as it regains commercial momentum and expands utilization and its customer base."
- Forums
- ASX - By Stock
- Nova Eye Medical (EYE) Discussion
SGHT guidance is weak and hopefully a reflection of them losing...
-
- There are more pages in this discussion • 721 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EYE (ASX) to my watchlist
(20min delay)
|
|||||
Last
22.0¢ |
Change
0.005(2.33%) |
Mkt cap ! $50.34M |
Open | High | Low | Value | Volume |
22.0¢ | 22.0¢ | 21.5¢ | $77.61K | 360.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 203513 | 21.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
22.0¢ | 31852 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 203513 | 0.210 |
4 | 128320 | 0.205 |
18 | 430320 | 0.200 |
2 | 18434 | 0.195 |
1 | 1400 | 0.180 |
Price($) | Vol. | No. |
---|---|---|
0.220 | 30000 | 1 |
0.225 | 7845 | 1 |
0.230 | 6750 | 2 |
0.235 | 110000 | 2 |
0.245 | 11000 | 1 |
Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
Featured News
EYE (ASX) Chart |